Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with limited treatment options in case of recurrence. Prostate-specific membrane antigen (PSMA) expression was demonstrated in microvascular endothelium of GBM and in vivo confirmed by [68Ga]Ga-PSMA-11 PET/CT in primary as well in recurrence tumor [1–4]. This knowledge opens a new way for targeted, PSMA-based treatment. However, it was suggested that uptake not in tumor cells, but in microvascular endothelium, could be characterized by quick washout.
A 54-year-old man 3 years after primary treatment including surgery and chemo-radiotherapy, with a recurrence of GBM revealed in the follow-up MRI, was referred for [68Ga]Ga-PSMA-11 PET/CT. The image demonstrated increased, homogenous uptake in the right parietal mass (SUVmax 10.3) with the tumor-to-liver ratio of 1.8. The patient was disqualified from surgery and radiotherapy and refused chemotherapy. [177Lu]Lu-PSMA-617 treatment was performed (8.39 GBq) with a dosimetry study [5].
The post-therapy images showed increased uptake in tumor mass during the first 24 h, with slow, decreased accumulation up to 14 days. The uptake in normal organs increased up to 3 h post injection and rapidly decreased in the next days (Figs. 1 and 2). The absorbed dose for the tumor was 14.07 Gy, kidney 0.14 Gy, liver 1.67 Gy, and for whole body 0.49 Gy. To our knowledge, dosimetry study in the treatment of GBM with [177Lu]Lu-PSMA-617 has not been previously reported. The post-therapy images proved the possibility of targeted therapy with α/β-emitters with no quick as postulated washout in the tumor.
Compliance with ethical standards
This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the individual participant included in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
This article is part of the Topical Collection on Image of the month.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Wernicke AG, Edgar MA, Lavi E, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135:1486–1489. doi: 10.5858/arpa.2010-0740-OA. [DOI] [PubMed] [Google Scholar]
- 2.Marafi F, Sasikumar A, Fathallah W, Esmail A. 18F-PSMA 1007 Brain PET/CT imaging in glioma recurrence. Clin Nucl Med. 2020;45:e61–e62. doi: 10.1097/RLU.0000000000002668. [DOI] [PubMed] [Google Scholar]
- 3.Kunikowska J, Królicki B, Królicki L. Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy. Eur J Nucl Med Mol Imaging. 2018;45:886–887. doi: 10.1007/s00259-018-3934-2. [DOI] [PubMed] [Google Scholar]
- 4.Kunikowska J, Kuliński R, Muylle K, Koziara H. Królicki L 68Ga PSMA-11 PET/CT: a new imaging option for recurrent glioblastoma multiforme? Clin Nucl Med. 2020;45:11–18. doi: 10.1097/RLU.0000000000002806. [DOI] [PubMed] [Google Scholar]
- 5.Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W. Dosimetry in clinical radionuclide therapy: the devil is in the detail. Eur J Nucl Med Mol Imaging. 2017;44:2137–2139. doi: 10.1007/s00259-017-3820-3. [DOI] [PubMed] [Google Scholar]